Britain’s drug regulator approved the Alzheimer’s drug Kisunla on Wednesday, but the government won’t be paying for it after ...

Eli Lilly's treatment for early Alzheimer's was deemed too expensive for wide use by UK's cost-effectiveness body on ...

Travel difficulties, communication issues and stress are stopping patients across the U.K. from attending their hospital ...

(Reuters) -British finance minister Rachel Reeves is expected to impose national insurance on employers' pension contribution ...

Wes Streeting has suggested that no-show patients may be fined in the future because NHS lost £1 billion to nearly eight million missed NHS appointments in the last year.

For the second time in recent months, a U.K. agency said the limited benefits of a new Alzheimer’s drug do not justify its ...

A first-of-its-kind study testing an mRNA vaccine for norovirus, the highly contagious winter vomiting bug, is launching in ...

The UK Government has recommended offering a COVID-19 booster vaccination in autumn, 2024, to individuals at high risk of ...

As senior national health leaders, we have seen firsthand the devastation of health crises unaddressed. The coronavirus pandemic, one of the greatest public health challenges in modern history, cost ...

The government has been urged to prioritize funding and fast-track the implementation of the National Community Health ...

A new Alzheimer’s drug has been rejected for widespread use in the health service in England after the health spending ...

Initiatives aimed at getting homeless people healthier and off the streets are running up against new, aggressive crackdowns.